Ranked #2,301 of 8,699 institutional investors
Fcpm III Services B.v.
Naarden, P7
$1.04B
US stock portfolio at live prices · today +$20.9M (+2.05%)
Market closed. Prices as of Nov 20, 7:11 AM ET
- Value at quarter end (Q3 2026)
- $1.06B
- Change from Q2 2026
- +$310.3M (+41.35%)
- Positions
- 10 · 4 new, 0 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: none$308M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesBRVE 40.4%KRSA 7.47%VOR 6.06%DYN 5.53%AURA 3.52%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| BRVE Braveheart Bio, Inc. | 21,826,024 | $421M | 40.4% | New |
| KRSA Korsana Biosciences, Inc. | 2,192,155 | $77.7M | 7.47% | New |
| VOR Vor Biopharma Inc. | 3,405,279 | $63.1M | 6.06% | Reduced −17% |
| DYN Dyne Therapeutics, Inc. | 3,586,796 | $57.5M | 5.53% | Reduced −7% |
| AURA Aura Biosciences, Inc. | 5,248,841 | $36.6M | 3.52% | Added +29% |
| REPL Replimune Group, Inc. | 1,720,500 | $33.1M | 3.18% | Reduced −39% |
| MPLT MapLight Therapeutics, Inc. | 4,428,328 | $28.4M | 2.73% | Added +37% |
| BCYC Bicycle Therapeutics plc | 3,468,430 | $10.6M | 1.02% | Unchanged |
| TARS Tarsus Pharmaceuticals, Inc. | 64,087 | $5.0M | 0.48% | New |
| LSTA Lisata Therapeutics, Inc. | 297,478 | $271K | <0.1% | New |